Bacterial infections:

Indications for: MACROBID

For the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus.

Limitations of Use:

Not indicated for the treatment of pyelonephritis or perinephric abscesses.

Clinical Trials:

In controlled clinical trials comparing Macrobid 100mg every 12 hours and Macrodantin 50mg every 6 hours for the treatment of acute uncomplicated UTIs, approximately 75% microbiologic eradication of susceptible pathogens was observed in each treatment group.

Adult Dosage:

Take with meals. 100mg every 12hrs for 7 days.

Children Dosage:

Not established.

MACROBID Contraindications:

Anuria, oliguria, CrCl <60mL/min. Neonates <1 month of age. Labor & delivery. Pregnancy at term. History of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.

MACROBID Warnings/Precautions:

Not for treating pyelonephritis or perinephric abscesses. Discontinue if pulmonary reactions, hepatic disorders, or hemolysis occurs. Renal insufficiency; monitor (esp. in elderly). G6PD or Vit. B deficiency. Anemia. Diabetes. Electrolyte imbalance. Monitor renal function and pulmonary condition in long-term use. Debilitated. Pregnancy (Cat.B). Nursing mothers: not recommended.

MACROBID Classification:


MACROBID Interactions:

Reduced absorption by magnesium trisilicate. Uricosurics (eg, probenecid, sulfinpyrazone) may inhibit tubular secretion. May cause false (+) glucose test with Benedict's or Fehling's solution.

Adverse Reactions:

Nausea, headache, flatulence, dizziness, alopecia; C. diff-associated diarrhea, pulmonary disorders, hepatic damage, hemolytic anemia, peripheral neuropathy (may be irreversible), anaphylaxis, blood dyscrasias; rare: exfoliative dermatitis, Stevens-Johnson syndrome, aplastic anemia.


Hepatic. ~90% serum protein bound.

Drug Elimination:

Renal. Half-life: 0.72–0.78 hours.

How Supplied: